for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gene Techno Science Co Ltd (Parent)

4584.T

Latest Trade

971.00JPY

Change

51.00(+5.54%)

Volume

296,900

Today's Range

909.00

 - 

971.00

52 Week Range

568.00

 - 

1,044.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
920.00
Open
910.00
Volume
296,900
3M AVG Volume
5.15
Today's High
971.00
Today's Low
909.00
52 Week High
1,044.00
52 Week Low
568.00
Shares Out (MIL)
27.65
Market Cap (MIL)
25,628.76
Forward P/E
-3.56
Dividend (Yield %)
--

Next Event

Q3 2020 Gene Techno Science Co Ltd Earnings Release

Latest Developments

More

Gene Techno Science signs collaborative research agreement with chromocenter

Gene Techno Science commences phase III clinical trial for biosimilars in ophthalmology

Gene Techno Science raises 301.9 mln yen via private placement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gene Techno Science Co Ltd (Parent)

Gene Techno Science Co., Ltd. is primarily engaged in the development of biopharmaceuticals including biosimilars and new drugs. The biopharmaceuticals are medicines based on the mechanism of living body, can not be achieved with existing low molecular medicines, and are produced by biotechnology including genetic engineering. The biopharmaceuticals business is engaged in the research and development of biopharmaceuticals. The biosimilars and new drugs business is engaged in research and development of biosimilars and new drugs, as well launching regenerative medicine field as new business. It also has a pipeline with multiple developed products.

Industry

Biotechnology & Drugs

Contact Info

3F, Kanayama Bldg., 1-2-12, Shinkawa

+81.3.62229547

https://www.g-gts.com/

Executive Leadership

Masaharu Tani

President, Representative Director

Yoshikazu Amano

Chief Technology Officer, Executive Officer, Director

Masayuki Kawakami

Executive Officer, Chief Director of Research & Development

Shinya Kurebayashi

Executive Officer, Chief Director of Business Development

Eisaku Nakamura

Executive Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2020(E)

0.0K
EPS (JPY)

2020(E)

-260.400
Price To Earnings (TTM)
--
Price To Sales (TTM)
24.48
Price To Book (MRQ)
11.42
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.11
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-293.46
Return on Equity (TTM)
-255.61

Latest News

Latest News

BRIEF-Gene Techno Science commences phase III clinical trial for biosimilars in ophthalmology

* Says it commenced the phase III clinical trial for biosimilars in ophthalmology, which is a joint work between the co and Senju Pharmaceutical Co Ltd

BRIEF-Gene Techno Science sets up JV

* Says it established Sapporo-based JV with AIN HOLDINGS INC , North Pacific Bank,LTD. and a Sapporo-based investment limited liability partnership

BRIEF-Gene Techno Science announces change of chairman and president

* Says it appoints current president Masanari Kawaminami as new chairman, Masaharu Tani as new president, effective on April 1

BRIEF-Gene Techno Science forms cooperation with ITOCHU CHEMICAL FRONTIER Corp

* Says the co to jointly develop biosimilars technology with ITOCHU CHEMICAL FRONTIER Corporation

BRIEF-Gene Techno Science signs joint research and development contract with Juntendo University

* Says it signed a joint research and development contract for new immunosuppressive therapy with Juntendo University on Feb. 27

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up